Overall, a greater proportion of patients in the P/MC treatment arm were able to consume the entire preparation as instructed compared with patients receiving 2L PEG-3350 and bisacodyl tablets (99.0% vs 89.9%; P! .0001). Compared
with patients receiving P/MC, a larger proportion of patients in the 2L PEG-3350 and bisacodyl tablets treatment arm
would refuse the preparation if another colonoscopy were needed in the future (1.7% vs 13.5%; P!.0001). Only a small
percentage of patients receiving P/MC and 2L PEG-3350 and bisacodyl tablets had undergone a colonoscopy within the
past 3 years (14.9% vs 19.5%; P Z .0793).